Evidence map›Paper›PMID 37795493›Full record

ReviewJournal of inflammation research2023

Advances in the Study of Plant-Derived Vesicle-Like Nanoparticles in Inflammatory Diseases.

Xuejun Tan, Yukun Xu, Sirui Zhou, Mingyue Pan, Yue Cao, Xiuping Cai, Qing Zhao, Kewei Zhao

Open access · goldAbstract readReview
In one paragraph

Review in Journal of inflammation research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 7 citations in OpenAlex.

  1. Green nanomedicine for cancer therapy.Chinese medical journal · 2026
    Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Xuejun TanThe Third Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.ORCID 0009-0000-3834-3146
Yukun XuThe Third Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.ORCID 0009-0008-1639-4901
Sirui ZhouThe Third Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.ORCID 0009-0004-0600-6769
Mingyue PanThe Third Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.ORCID 0009-0008-1426-6623
Yue CaoThe Third Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
Xiuping CaiGuangzhou Key Laboratory of Chinese Medicine Research on Prevention and Treatment of Osteoporosis, The Third Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
Qing Zhao *The Third Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
Kewei Zhao *The Third Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
Guangzhou University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

All humans are universally affected by inflammatory diseases, and there is an urgent need to identify new anti-inflammatory drugs with good therapeutic benefits and minimal side effects to the organism. Recently, it has been found that plant-derived vesicle-like nanoparticles (PDVLNs) have good biocompatibility, with their active ingredients exhibiting good therapeutic effects on inflammation. They can also be used as drug carriers for targeted delivery of anti-inflammatory drugs. Therefore, PDVLNs represent a popular research area for novel anti-inflammatory drugs. This paper details the origin, biological functions, isolation and purification, and identification of PDVLNs, as well as the therapeutic effects of their intrinsic bioactive components on inflammatory diseases. It also introduces their targets as drug carriers to facilitate the development and application of PDVLNs anti-inflammatory drugs.

Indexed as

inflammationinflammatory diseasesplantvesicle-like nanoparticles

Identifiers

PMID37795493
PMCPMC10547002
OpenAlexW4387172233

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.